- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 28.04. | AACR: Merck's Keytruda prevents head and neck cancer from returning in industry-first win | ||
| 28.04. | Merck KGaA springs back into M&A game with $3.9B buyout of Pfizer spinout SpringWorks | ||
| 28.04. | French health authorities suspend use of Valneva's chikungunya vaccine in older adults to probe 3 hospitalizations, one death | ||
| 28.04. | Regeneron scores EU nod for bispecific antibody Lynozyfic, setting up clash with J&J and Pfizer | ||
| 28.04. | 'Deviated from core': Akeso CEO tries to reset expectations of bispecific's survival readout amid market tumult | ||
| 27.04. | As J&J aims to 'fundamentally change' how bladder cancer type is treated, ImmunityBio plays defense | ||
| 25.04. | Summit stock crashes as Akeso shares bispecific's first overall survival data in Keytruda head-to-head trial | ||
| 25.04. | With industry's onshoring tide rolling on, Amgen blueprints $900M expansion at Ohio biomanufacturing plant | ||
| 25.04. | Following pharma's tariff trend, AbbVie unveils $10B US investment in 10 years | ||
| 25.04. | Gilead, 'closely attuned to' potential US policy shifts, stands by long-acting PrEP launch | ||
| 25.04. | Akeso, Sino Biopharm's Anniko enters crowded PD-1 market with FDA approval in head and neck cancer subtype | ||
| 25.04. | US court decision stops compounders from making knockoffs of Novo Nordisk's semaglutide | ||
| 25.04. | Angus on Angus: A Fierce oncology discussion | ||
| 25.04. | Fierce Pharma Asia-Enhertu's first-line win; Akeso bispecific's positive readout; Regeneron, Fujifilm's $3B deal | ||
| 25.04. | Merck KGaA confirms late-stage talks with SpringWorks about $3.5B buyout | ||
| 24.04. | Thermo Fisher jumps on the US investment bandwagon with $2B in additional spending | ||
| 24.04. | Halozyme sues Merck over subcutaneous Keytruda as licensing talks fall through | ||
| 24.04. | UCB partners with Dr. Pimple Popper in ongoing hidradenitis suppurativa campaign | ||
| 24.04. | BMS shrugs off Cobenfy's schizophrenia hit as it gears up for Alzheimer's psychosis readout, 7 trial starts | ||
| 24.04. | Merck 'willing to work' with Trump administration on price gap between US, international medicines | ||
| 24.04. | Sanofi and Regeneron's high-flying Dupixent on course for an 'inflection year' in COPD | ||
| 24.04. | Roche moves to mitigate US tariff impact amid discussions with global governments | ||
| 24.04. | Lupin recalls nearly 3,000 bottles of OCD medication in the US after subpar stability testing results | ||
| 24.04. | Texas outsourcer in Lilly's compounded tirzepatide lawsuit hit with FDA warning letter | ||
| 23.04. | Tariff hits to generic drugs could 'blow back on everybody' without supply chain resilience, says USP chief |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .